Movement Alert｜PegBio Falls 5.14% in Regular Trading, Pullback Continues Amid Lock-Up Expiry Concerns Following Multi-Day Rally

Market Focus

05/21

On May 21, PegBio Co Ltd (02565.HK) fell 5.14% in regular trading, trading at HK$14.38/share with trading volume of HK$29.44 million, extending a multi-day pullback after its explosive rally earlier in the week.

The decline follows concerns over a share lock-up expiry period. The stock had surged over 100% on May 18 after the company announced a strategic commercialization partnership with Tengrui Pharma for its GLP-1 drug Paidakang (Vipeptanate Injection) targeting the Chinese mainland market. Under the agreement, Tengrui will pay approximately HK$140 million in licensing fees, with both parties targeting cumulative sales exceeding RMB 10 billion. The stock continued climbing on May 19 and May 20 before reversing course.

The current retreat contrasts with the broader Biotechnology sector, where peers including AKESO (+7.13%), REMEGEN (+5.13%), INNOVENT BIO (+3.97%), BEIGENE (+3.04%), and 3SBIO (+2.44%) posted gains during the session.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1162345639"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162345639\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162345639?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 10:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162345639","market":"us","top_or_hot":-1,"title":"Movement Alert｜PegBio Falls 5.14% in Regular Trading, Pullback Continues Amid Lock-Up Expiry Concerns Following Multi-Day Rally","media":"Market Focus","content":"<p><p>On May 21, PegBio Co Ltd (02565.HK) fell 5.14% in regular trading, trading at HK$14.38/share with trading volume of HK$29.44 million, extending a multi-day pullback after its explosive rally earlier in the week.</p><p>The decline follows concerns over a share lock-up expiry period. The stock had surged over 100% on May 18 after the company announced a strategic commercialization partnership with Tengrui Pharma for its GLP-1 drug Paidakang (Vipeptanate Injection) targeting the Chinese mainland market. Under the agreement, Tengrui will pay approximately HK$140 million in licensing fees, with both parties targeting cumulative sales exceeding RMB 10 billion. The stock continued climbing on May 19 and May 20 before reversing course.</p><p>The current retreat contrasts with the broader Biotechnology sector, where peers including AKESO (+7.13%), REMEGEN (+5.13%), INNOVENT BIO (+3.97%), BEIGENE (+3.04%), and 3SBIO (+2.44%) posted gains during the session.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PegBio Falls 5.14% in Regular Trading, Pullback Continues Amid Lock-Up Expiry Concerns Following Multi-Day Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PegBio Falls 5.14% in Regular Trading, Pullback Continues Amid Lock-Up Expiry Concerns Following Multi-Day Rally\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time smaller\">2026-05-21 10:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><p>On May 21, PegBio Co Ltd (02565.HK) fell 5.14% in regular trading, trading at HK$14.38/share with trading volume of HK$29.44 million, extending a multi-day pullback after its explosive rally earlier in the week.</p><p>The decline follows concerns over a share lock-up expiry period. The stock had surged over 100% on May 18 after the company announced a strategic commercialization partnership with Tengrui Pharma for its GLP-1 drug Paidakang (Vipeptanate Injection) targeting the Chinese mainland market. Under the agreement, Tengrui will pay approximately HK$140 million in licensing fees, with both parties targeting cumulative sales exceeding RMB 10 billion. The stock continued climbing on May 19 and May 20 before reversing course.</p><p>The current retreat contrasts with the broader Biotechnology sector, where peers including AKESO (+7.13%), REMEGEN (+5.13%), INNOVENT BIO (+3.97%), BEIGENE (+3.04%), and 3SBIO (+2.44%) posted gains during the session.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物醫藥-B","start_time":0,"source_url":"","article_id":"1162345639","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162345639","pubTimestamp":1779329149,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 21, PegBio Co Ltd (02565.HK) fell 5.14% in regular trading, trading at HK$14.38/share with trading volume of HK$29.44 million, extending a multi-day pullback after its explosive rally earlier...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"走势警报|PegBio常规交易下跌5.14%，在多日上涨后，禁售期到期担忧持续回调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"On May 21, PegBio Co Ltd (02565.HK) fell 5.14% in regular trading, trading at HK$14.38/share with trading volume of HK$29.44 million, extending a multi-day pullback after its explosive rally earlier in the week.The decline follows concerns over a share lock-up expiry period. The stock had surged over 100% on May 18 after the company announced a strategic commercialization partnership with Tengrui Pharma for its GLP-1 drug Paidakang (Vipeptanate Injection) targeting the Chinese mainland market. Under the agreement, Tengrui will pay approximately HK$140 million in licensing fees, with both parties targeting cumulative sales exceeding RMB 10 billion. The stock continued climbing on May 19 and May 20 before reversing course.The current retreat contrasts with the broader Biotechnology sector, where peers including AKESO (+7.13%), REMEGEN (+5.13%), INNOVENT BIO (+3.97%), BEIGENE (+3.04%), and 3SBIO (+2.44%) posted gains during the session.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}